NGL Fine-Chem Limited (NSE:NGLFINE)

Market Cap	8.02B
Revenue (ttm)	3.73B
Net Income (ttm)	325.99M
Shares Out	n/a
EPS (ttm)	52.78
PE Ratio	24.62
Forward PE	n/a
Dividend	1.75 (0.14%)
Ex-Dividend Date	Aug 16, 2024

Volume	324
Average Volume	2,619
Open	1,285.60
Previous Close	1,285.60
Day's Range	1,259.90 - 1,285.60
52-Week Range	957.00 - 2,777.95
Beta	0.62
RSI	61.78
Earnings Date	May 12, 2025

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, f...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1981
• Employees: 682
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NGLFINE

Financial Performance

In 2023, NGL Fine-Chem's revenue was 3.39 billion, an increase of 21.79% compared to the previous year's 2.78 billion. Earnings were 413.17 million, an increase of 101.58%.